Journal article
Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice.
-
Wilke C
Hertie Institute for Clinical Brain Research (HIH), Center of Neurology, University of Tübingen, Tübingen, Germany.
-
Haas E
Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
-
Reetz K
Department of Neurology, RWTH Aachen University, Aachen, Germany.
-
Faber J
Department of Neurology, University Hospital Bonn, Bonn, Germany.
-
Garcia-Moreno H
Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
-
Santana MM
Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
-
van de Warrenburg B
Donders Institute for Brain, Cognition, and Behaviour, Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.
-
Hengel H
Hertie Institute for Clinical Brain Research (HIH), Center of Neurology, University of Tübingen, Tübingen, Germany.
-
Lima M
Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal.
-
Filla A
Department of Neuroscience, and Reproductive and Odontostomatological Sciences, Federico II University Naples, Naples, Italy.
-
Durr A
Sorbonne Université, Institut du Cerveau et de la Moelle épinière (ICM), AP-HP, Inserm, CNRS, University Hospital Pitié-Salpêtrière, Paris, France.
-
Melegh B
Department of Medical Genetics, Szentagothai Research Center, University of Pécs Medical School, Pécs, Hungary.
-
Masciullo M
Spinal Rehabilitation Lab (SPIRE), IRCCS Fondazione Santa Lucia, Rome, Italy.
-
Infante J
Service of Neurology, University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria (UC), Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Santander, Spain.
-
Giunti P
Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
-
Neumann M
German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany.
-
de Vries J
Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
-
Pereira de Almeida L
Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
-
Rakowicz M
First Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland.
-
Jacobi H
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
-
Schüle R
Hertie Institute for Clinical Brain Research (HIH), Center of Neurology, University of Tübingen, Tübingen, Germany.
-
Kaeser SA
Hertie Institute for Clinical Brain Research (HIH), Center of Neurology, University of Tübingen, Tübingen, Germany.
-
Kuhle J
Neurology, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
-
Klockgether T
Department of Neurology, University Hospital Bonn, Bonn, Germany.
-
Schöls L
Hertie Institute for Clinical Brain Research (HIH), Center of Neurology, University of Tübingen, Tübingen, Germany.
-
Barro C
Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
-
Hübener-Schmid J
Hertie Institute for Clinical Brain Research (HIH), Center of Neurology, University of Tübingen, Tübingen, Germany.
-
Synofzik M
Show more…
Published in:
- EMBO molecular medicine. - 2020
English
With molecular treatments coming into reach for spinocerebellar ataxia type 3 (SCA3), easily accessible, cross-species validated biomarkers for human and preclinical trials are warranted, particularly for the preataxic disease stage. We assessed serum levels of neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) in ataxic and preataxic subjects of two independent multicentric SCA3 cohorts and in a SCA3 knock-in mouse model. Ataxic SCA3 subjects showed increased levels of both NfL and pNfH. In preataxic subjects, NfL levels increased with proximity to the individual expected onset of ataxia, with significant NfL elevations already 7.5 years before onset. Cross-sectional NfL levels correlated with both disease severity and longitudinal disease progression. Blood NfL and pNfH increases in human SCA3 were each paralleled by similar changes in SCA3 knock-in mice, here also starting already at the presymptomatic stage, closely following ataxin-3 aggregation and preceding Purkinje cell loss in the brain. Blood neurofilaments, particularly NfL, might thus provide easily accessible, cross-species validated biomarkers in both ataxic and preataxic SCA3, associated with earliest neuropathological changes, and serve as progression, proximity-to-onset and, potentially, treatment-response markers in both human and preclinical SCA3 trials.
-
Language
-
-
Open access status
-
gold
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/92662
Statistics
Document views: 81
File downloads: